Novel Approach is Enhancing the Sensitivity of Bioanalytical,
Biomarker Validation, Pharmacokinetic and Food Research LC/MS Analyses
MILFORD, Mass.--(BUSINESS WIRE)--Nov. 16, 2015--
Waters Corporation (NYSE:WAT) today announced that the Waters®
ionKey/MS™ System has received an R&D Magazine R&D 100 Award as one
of the 100 most technologically innovative products to be introduced
over the past year.
“I’d like to thank the publisher and editors of R&D Magazine and the
judges for choosing our ionKey/MS System for this award,” said Ian King,
Vice President – Separations Science, Waters Division. “The response of
scientists to the product has been extremely gratifying and our
development team and our collaborators deserve all the credit for
bringing this product to market despite the technological challenges
this novel approach presented.”
Intended for use with Waters
ACQUITY® UPLC® M-Class System and a range of
Waters mass spectrometers, including the Xevo® TQ-S , Xevo
G2-XS and the Synapt® G2-Si, the Waters ionKey/MS System
physically integrates a UPLC separation into the mass spectrometer
producing up to a 40x improvement in sensitivity, enabling scientists to
achieve unparalleled separation and detection of compounds. The
ionKey/MS System’s iKey Microfluidic Separation Device, which is about
the size of a smart phone, contains the fluidic connections,
electronics, ESI interface, column heater, eCord™ Intelligent Chip
Technology and the 1.7 micron UPLC grade particles packed inside a 150
micron I.D. channel to perform hundreds upon hundreds of UPLC
separations reproducibly and reliably without a degradation in
performance.
For quantifying extremely low abundant analytes, researchers often turn
to microscale LC techniques employing microfluidics because of their
ability to optimize ionization efficiency and improve MS sampling. In
their 2014 article in the journal Bioanalysis, Merck
scientists beta-testing the ionKey/MS System reported that the method
they developed achieved an overall 20-fold increase in sensitivity (0.5
picomoles vs. 11 picomoles) for endogenous levels of GLP-1 in human
plasma, a faster run time (nine minutes vs. 35 minutes), increased
specificity and resolution over a more traditional LC-MS/MS method.
Since the R&D 100 award competition began, Waters has won nine R&D 100
awards, most recently for its CORTECS® 1.6 micron analytical
columns, Oasis® 96-Well (micro) Elution Extraction Plate,
XTERRA® Columns, ACQUITY UPLC System and the ACQUITY UPC2®
System.
For more information: www.waters.com/ionkey
About the R&D 100 Awards
Widely recognized as the “Oscars of Invention”, the R&D 100 Awards
identify and celebrate the top technology products of the year. Past
winners have included sophisticated testing equipment, innovative new
materials, chemistry breakthroughs, biomedical products, consumer items,
and high-energy physics. The R&D 100 Awards spans industry, academia,
and government-sponsored research.
For more information www.rdmag.com
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT) develops and manufactures advanced
analytical and material science technologies for laboratory dependent
organizations. For more than 50 years, the company has pioneered a
connected portfolio of separations science, laboratory information
management, mass spectrometry and thermal analysis systems.
Waters, XTERRA, Oasis, Xevo, eCord, Synapt, CORTECS, ACQUITY, ACQUITY
UPLC, ionKey/MS and UPLC are trademarks of Waters Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151116006472/en/
Source: Waters Corporation
Waters Corporation
Brian J. Murphy, +1 508-482-2614
Public
Relations Manager
brian_j_murphy@waters.com